Research fuels our mission to end cancer
Many of the greatest minds in cancer research are at MD Anderson. They're here because MD Anderson offers a unique environment that accelerates their ability to end cancer. They collaborate with other cancer experts – in different research areas and with the world's leading cancer doctors. Bright students and trainees contribute further to our dynamic research environment. Discoveries are fueled by vast research support and resources. Tomorrow's medicine is available to our patients first since we have the most cancer clinical trials in the world. These research efforts work in parallel to fight cancer through prevention, early diagnosis, effective therapies and scientific breakthroughs.
Research Productivity by the Numbers
in NIH funding secured
peer-review articles published
active clinical trials
In Fiscal Year 2017, our researchers' productivity was impressive. By securing federal funding, publishing in peer-review journals and bringing research into the clinic, our researchers uphold our status as one of the nation’s top comprehensive cancer centers.
Departments, Labs and Institutes
MD Anderson has many parts, including departments, labs and institutes, but the sum of those parts is ending cancer. MD Anderson's reach is comprehensive when it comes to eliminating cancer.
Our laboratories cover the full breadth of cancer research. They’re led by some of the leading scientists and physicians in the world.
Scientists from different disciplines come together to focus on a common area in our research institutes.
Jim Allison's Research
Immunotherapy pioneer named among TIME's 100 most influential people
Moon Shots Program
Inspired by an unprecedented era of scientific discovery a generation ago, the Moon Shots Program™ was launched by MD Anderson as an ambitious plan to make a giant leap in cancer research to benefit patients.Learn more about the Moon Shots Program
Resurrected targeted therapy offers new hope for lung cancer
Patients with metastatic non-small cell lung cancer carrying a highly treatment-resistant mutation, called EGFR exon 20 insertion, have had no effective treatment options in the past. These patients have a progression free survival of about two months, and a response rate of less than 20%. Lung Cancer Moon Shot™ researchers have resurrected an abandoned EGFR inhibitor, poziotinib, and discovered that it produces unprecedented response rates in patients with this harsh non-small cell lung cancer mutation.